<SEC-DOCUMENT>0001144204-17-015950.txt : 20170322
<SEC-HEADER>0001144204-17-015950.hdr.sgml : 20170322
<ACCEPTANCE-DATETIME>20170322091114
ACCESSION NUMBER:		0001144204-17-015950
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170322
FILED AS OF DATE:		20170322
DATE AS OF CHANGE:		20170322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		17705773

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		5 HACHAROSHET ST.
		CITY:			RAANANA
		STATE:			L3
		ZIP:			4365603
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v462398_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of March, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: <B>001-36000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>XTL Biopharmaceuticals Ltd.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>5 Hacharoshet St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PO Box 4423</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Raanana 4365603, Israel</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085,
File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 333-194338).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B><IMG SRC="pg2.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL BIOPHARMACEUTICALS ANNOUNCES CLOSING
OF $2.8 MILLION PRIVATE PLACEMENT FROM EXISTING INVESTORS&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Raanana, Israel, March 22, 2017 &ndash;
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB)</B>&nbsp;(TASE:XTLB.TA) (&ldquo;XTL&rdquo; or the &ldquo;Company&rdquo;)<B>,&nbsp;</B>a
clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has closed its
private offering of securities for proceeds of $2.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, previously
announced on March 7, 2017, the Company issued and sold 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00
per ADS. Additionally, for each ADS purchased by investors, the investors received an unregistered warrant to purchase one ADS.
The Company has agreed to hold a shareholder meeting to increase its authorized ordinary shares to allow for the full exercise
of the warrants (the &ldquo;Authorized Capital Increase&rdquo;). The warrants have a term of five and a half years, an exercise
price of $2.30 per ADS and will be exercisable on the later of the effectiveness of the Authorized Share Increase or six months
following the issuance date.&nbsp;There was no placement agent in connection with this private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ADSs and warrants described above were
offered and sold in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and Regulation D promulgated thereunder and, along with the ADSs issuable upon their exercise, have not been registered
under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable
exemption from such registration requirements. The investors have entered into lockup agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute
an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation
of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>About XTL Biopharmaceuticals Ltd</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL Biopharmaceuticals
Ltd. is a&nbsp;clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune
diseases. The Company&rsquo;s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of autoimmune diseases
including systemic lupus erythematosus (SLE) and Sj&ouml;gren&rsquo;s Syndrome (SS). The few treatments currently on the market
for these diseases are not effective enough for most patients and some have significant side effects. hCDR1 has robust clinical
data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than&nbsp;40 peer
reviewed scientific journals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL is&nbsp;traded
on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following
indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 20%"></TD>
    <TD STYLE="vertical-align: top; width: 61%"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;<IMG SRC="pg2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Forward-Looking Statements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain forward-looking
statements, about XTL&rsquo;s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as &quot;believe,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;may,&quot;
&quot;should&quot; or &quot;anticipate&quot; or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL&rsquo;s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL&rsquo;s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL&rsquo;s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL&rsquo;s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares which are included in our Form 20-F filed with the U.S. Securities
and Exchange Commission on March 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>For further information, please contact:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations, XTL Biopharmaceuticals
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email:&nbsp;<FONT STYLE="color: blue"><U>ir@xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><U>www.xtlbio.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>XTL BIOPHARMACEUTICALS LTD.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 60%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 5%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 35%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 22, 2017</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>pg2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !2 /X# 2(  A$! Q$!_\0
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M2I/!'T->MXAY;7Q4J6=T%STI15VM;.VNW0^8\.,SHX.%7(\2^2M%NR>G,O\
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M2(<<\^E?%OCW]BGQ1X.U63^S-MS$6Q&<['3_ (%D8K]5# K1[2H*],8K)O\
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MG(NQ<>E+7YW.4ZC<JC;;ZO<_184X02C37*ET6P4444BPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
